<DOC>
	<DOCNO>NCT00093470</DOCNO>
	<brief_summary>This randomized phase III trial study tipifarnib treat patient acute myeloid leukemia ( AML ) remission . Tipifarnib may stop growth cancer cell block enzymes necessary growth . It yet know whether tipifarnib effective observation alone prevent recurrence AML .</brief_summary>
	<brief_title>Tipifarnib Treating Patients With Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare R115777 ( tipifarnib ) maintenance therapy observation respect disease-free survival ( DFS ) patient acute myeloid leukemia ( AML ) second subsequent complete remission complete response ( CR ) follow primary induction failure . SECONDARY OBJECTIVES : I . To compare overall survival patient arm . II . To evaluate long-term safety toxicity extend administration R115777 AML patient remission . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive tipifarnib orally ( PO ) twice daily ( BID ) day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM B : Patients undergo observation . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Patients eligible enter study must fall one category : Patients first remission follow primary induction failure receive least two chemotherapy induction regimens Patients second subsequent remission Patients &gt; 60 year old first remission Patients must complete remission ( CR ) morphologic remission ( MR ) blood count bone marrow study enter study Confirmatory bone marrow must perform = &lt; 2 week prior randomization Patients must morphologic proof ( bone marrow aspirate , smear touch prep marrow biopsy ) AML one follow type prior achievement CR/MR Acute myeloblastic leukemia , minimal differentiation ( FrenchAmericanBritish [ FAB ] M0 ) Acute myeloblastic leukemia without differentiation ( FAB M1 ) Acute myeloblastic leukemia maturation ( FAB M2 ) Acute myelomonocytic leukemia ( FAB M4 ) Acute monocytic leukemia ( FAB M5 ) Acute erythroleukemia ( FAB M6 ) Acute megakaryocytic leukemia ( FAB M7 ) Refractory anemia excess blast transformation ( RAEBT ) AML World Health Organization ( WHO ) criteria Acute myeloid leukemia multilineage dysplasia Patients must register within 60 day completion therapy current remission All patient eligible study entry : Patients receive consolidation therapy Patients receive consolidation post remission therapy Patients autologous stem cell transplant Patients history extramedullary disease eligible complete remission time study entry longer require therapy extramedullary disease Women childbearing potential sexually active male strongly advise use accept effective method contraception Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Absolute neutrophil count ( ANC ) &gt; = 1000/mm^3 Platelet count &gt; = 50,000/mm^3 Patients acute promyelocytic leukemia ( FAB M3 ) Patients receive allogeneic transplant ( bone marrow transplant [ BMT ] peripheral stem cell transplant [ PSCT ] ) current remission ineligible ; patient allogeneic transplant previous remission currently remission subsequent relapse eligible Pregnant breastfeeding Allergy imidazole drug , clotrimazole ketoconazole , miconazole , econazole , terconazole ; include fluconazole , voriconazole , itraconazole Active cardiac pulmonary disease ; patient eligible disease medically control Active renal disease Active hepatic disease Patients take hepatic enzymeinducing anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Farnesyl Transferase Inhibitor</keyword>
	<keyword>R115777</keyword>
</DOC>